Center for Transport Oncophysics

拟议的交通肿瘤物理中心 (CTO) 是五个机构之间的合作项目。首席研究员是 Mauro Ferrari 博士 (UTHSC-H)，高级联合研究员是 Steven Curley 博士 (MDACC)。因此，所提出的 CTO 的第一个总体具体目标是构建一个理解癌症的“参考系统”，其中多维“单位向量”是跨越一组基本生物屏障的传输物理学的微分定律，因为它们在肿瘤发生中出现并进化（即“传输肿瘤物理学”）。第二个总体具体目标是证明 CTO 内开发的新系统和方法（多级系统、纳米梭、碳纳米管、金胶体、口服给药载体）在各自动物模型中的治疗效果。拟议的 CTO 将具有以下特点： 1. 单一科学框架（“传输肿瘤物理学”作为差异，生物屏障作为传输节点）； 2. 集成的“多重多尺度”方法（我们的数学、工程探针和成像仪器都是多尺度的，在这里用于研究生物屏障的多尺度结构），反映在共享核心和所有项目平台都可用作其他项目的核心； 3. “双重目的”操作方法，用于基本发现的工程转运探针也用于演示创新治疗方式，解决两个癌症焦点集群领域未解决的临床需求； 4.癌症焦点和动物模型的综合选择。第一个焦点组是肝癌，包括原发性和转移性（项目 1-2），第二个是结直肠癌（项目 3），其中有说服力的联系是结直肠癌的肝转移方面，以及在 Fidler 博士的指导下选择真诚再现人类疾病的统一动物模型。将通过试点项目机制在 CTO 的整个运作过程中开展进一步研究，解决交通肿瘤物理的互补和协同方面的问题。

The proposed Center for Transport OncoPhysics (CTO) is a collaborative program among five institutions. The Principal Investigator is Dr. Mauro Ferrari (UTHSC-H) and the Senior Co-Investigator is Dr. Steven Curley (MDACC). Thus, the first overall specific aim of the proposed CTO is to construct a ¿reference system¿ for the understanding of cancer, where the multi-dimensional ¿unit vectors¿ are the differential laws of transport physics across a fundamental set of biobarriers as they present themselves and evolve in tumorigenesis (i.e., ¿transport oncophysics¿). The second overarching Specific Aim is to demonstrate the therapeutic efficacy of the novel systems and approaches developed within the CTO (multi-stage systems, nanoshuttles, carbon nanotubes, gold colloids, oral administration carriers) in the respective animal models. The proposed CTO will feature: 1. A single scientific framework (¿transport oncophysics¿ as the differential, and biological barriers as the transport nodes); 2. An integrated ¿multiple multi-scale¿ approach (our mathematics, engineered probes, and imaging instrumentation are all multiscale, and are here employed to study the multiscale architecture of the biological barriers) reflected in shared cores and all project platforms being available to serve as cores for other projects; 3. A ¿dual-intent¿ operational approach, with the engineered transport probes used for basic discovery also being employed for the demonstration of innovative therapeutic modalities addressing unsolved clinical needs in two cancer focus cluster areas; 4. An integrated choice of cancer focus and animal models. The first focus cluster is liver cancer, both primary and metastatic (Projects 1-2), the second is colorectal cancer (Projects 3), with cogent connections being the liver metastasis aspect of colorectal cancer, and the choice of unified animal models that sincerely recapitulate human diseases, under the guidance of Dr. Fidler. Further investigations that address complementary and synergistic aspects of transport onco-physics will be launched throughout the operations of the CTO by means of the Pilot Projects mechanism.